Figure 1.

Immunohistochemical analysis of PRMT1 expression in ovarian serous carcinoma. (A) Negative control (no primary antibody). Tissue sections assigned scores of (B) 6 and (C) 12, following labeling with primary antibody against PRMT1. Scale bars, 100 µm. (D) Weighted score for PRMT1 expression in cancerous samples. PRMT1 expression was significantly higher in the platinum-resistant group than in the platinum-sensitive group. *P=0.019 (Mann-Whitney U test). (E) Receiver operating characteristic curve for determining the PRMT1 score cut-off to evaluate the sensitivity to platinum-based chemotherapy. Using a cutoff value of 3, the specificity was 68.0%, and the sensitivity was 69.2%. The area under the curve was 0.689 and the 95% confidence interval was 0.540-0.838. PRMT1, protein arginine methyltransferase 1.